Onconova Therapeutics, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics third quarter 2022 financial results and business update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a question and answer session. To ask a question at that time, please press star followed by the number one on your telephone keypad. If anyone has any difficulty hearing the conference, please press star zero for operator assistance. As a reminder, this call is being recorded today, November 14th, 2022. At this time, I'd like to turn the call over to Bruce Mackel of LifeSci Advisors.

Thank you, Operator, and welcome everyone to Ankenova's third quarter 2022 financial results and business update conference call. Earlier this afternoon, Ankenova issued a press release announcing its plans to conduct a Phase 1-2A clinical trial of nerazacyclib combined with letrozole in endometrial cancer and reported its financial results and business progress. If you have not yet seen this press release, it is available in the investors and media section of the company's website at www.oncanova.com. Following my introduction, we will hear from Onconova's President and CEO, Dr. Steve Fruchman, Chief Medical Officer, Dr. Mark Gelder, and Chief Operating Officer and Financial Officer, Mark Guerin. These prepared remarks will then be followed by a question and answer session. Before turning the call over to Ankanova's management team, I'd like to remind everyone that statements made during this call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made, as the underlying facts and circumstances may change. Except as required by law, Ankenova disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances. For more information on forward-looking statements, please review the disclaimer in today's press release. and the risk factors in the company's SEC filings.

With that, I will now turn the call over to Steve. Thank you, Bruce, and good afternoon, everybody.